Committee Composition

  Audit Nominating and Governance Compensation Strategic
John T. Henderson, M.D. Chairman of the Board Independent Director   Member of Nominating and Governance Committee Member of Compensation Committee Committee Chair for Strategic Committee
Lawrence C. Best Independent Director Member of Audit Committee     Member of Strategic Committee
Heiner Dreismann, Ph.D. Independent Director     Committee Chair for Compensation Committee Member of Strategic Committee
Walter Gilbert, Ph.D. Independent Director     Member of Compensation Committee  
Dennis Langer, M.D, J.D. Independent Director Member of Audit Committee Committee Chair for Nominating and Governance Committee    
Dennis Langer Director
Managing Partner, Phoenix IP Ventures

Dennis Langer, M.D., J.D. is a Director of the Company as of May 2004. He was previously Senior Vice President in Research and Development at GlaxoSmithKline and has a broad base of experience in innovative R&D companies such as Eli Lilly, Abbott and GD Searle. He is also a Clinical Professor at the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer has earned a J.D. (cum laude) from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University.
Holdings: 0 shares     View Transactions
S. Louise Phanstiel Independent Director Committee Chair for Audit Committee Member of Nominating and Governance Committee    
Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member Independent Director = Independent Director

Stock transaction information provided by EDGAR Online. Myriad Genetics, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.


Stock Quote (NASDAQ:MYGN)

Price:
37.05
Change:
+ 0.94
Open:
36.10
Previous Close:
36.11
Day High:
37.43
Day Low:
36.08
52 Week High:
42.50
52 Week Low:
20.02
Volume:
642,700
4:00 PM ET on Jul 29, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Investor Contact

Scott Gleason
(801) 584-1143
sgleason@myriad.com

Media Contact

Ron Rogers
Corporate Communications and Media Relations
(801) 584-3065
rrogers@myriad.com